Rekombinanter VEGF (Bevacizumab Biosimilar) Antikörper

Produktnummer ABIN7200653

Produktdetails anti-VEGF (Bevacizumab Biosimilar) Antikörper

Target: VEGF (Bevacizumab Biosimilar)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser VEGF (Bevacizumab Biosimilar) Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), In vivo Studies (in vivo)

Verwendungszweck: Bevacizumab Biosimilar, Human VEGF Monoclonal Antibody

Spezifität: The monoclonal antibody Bevacizumab biosimilar specifically binds to the human VEGF-A.

Produktmerkmale: Recombinant Humanized IgG1 Monoclonal Antibody generated from the same parent mouse antibody as ranibizumab.

Aufreinigung: Protein A affinity column

Reinheit: > 95% by SDS-PAGE under reducing conditions and HPLC.

Sterilität: 0.2 μm filtered

Endotoxin-Niveau: < 1 EU per 1 mg of the protein by the LAL method.

Immunogen: The monoclonal antibody Bevacizumab biosimilar was produced in the bevacizumab biosimilar CHO stable cell line.

Isotyp: IgG1 kappa

Anwendungsinformationen

Applikationshinweise: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by bevacizumab.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: PBS, pH 7.4, no stabilizers or preservatives.

Konservierungsmittel: Without preservative

Handhabung: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Lagerung: -20 °C

Informationen zur Lagerung: 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

Haltbarkeit: 12 months

Details zu VEGF (Bevacizumab Biosimilar)

Target: VEGF (Bevacizumab Biosimilar)

Abstract: VEGF (Bevacizumab Biosimilar) Produkte

Synonyme: MVCD1 antikoerper, VEGF antikoerper, VPF antikoerper, vascular endothelial growth factor A antikoerper, VEGFA antikoerper

Substanzklasse: Biosimilar

Hintergrund: Bevacizumab, the humanized anti-VEGF-A monoclonal antibody, produces angiogenesis inhibition and slows the growth of new blood vessels. As the first clinically available angiogenesis inhibitor in the United States, Bevacizumab is used for treatment of certain metastatic cancers, certain lung cancers, renal cancers, ovarian cancers, breast cancers, and glioblastoma multiforme of the brain.

Vascular endothelial growth factor A (VEGF-A) stimulates angiogenesis in a variety of cancers, including colorectal, lung, breast, glioblastoma, kidney, and ovarian cancers.